Please login to the form below

Cx601

This page shows the latest Cx601 news and features for those working in and with pharma, biotech and healthcare.

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Alofisel - previously Cx601 - is approved to treat complex perianal fistulas in adult patients with nonactive or mildly active luminal Crohn’s disease, when fistulas have shown an inadequate response to at

Latest news

Takeda offers €520m for stem cell firm TiGenix

CX601 has been classed as an orphan treatment for treating people who don’t respond to drug therapy. ... offers the best capabilities and resources to ensure access to Cx601 to patients worldwide.”.
CHMP backs Europe’s first allogeneic stem cell therapy

Takeda paid 25m upfront for rights to Cx601 for this indication outside the US, pledging another 355m in milestone payments, including 15m on approval by the EMA. ... TiGenix still owns the US rights to Cx601, considered a larger market opportunity for
TiGenix’s Crohn's fistulas treatment wins orphan drug status

The drug - currently known as Cx601 - could potentially treat ‘complex’perianal fistulas in patients with Crohn’s disease who have had an inadequate response to at least one conventional or biologic ... Meanwhile, TiGenix and partner Takeda has
TiGenix cell therapy for Crohn's fistulas shows long-term benefit

In ADMIRE-CD, 56% of patients treated with Cx601 and usual supportive care went into remission, compared to 39% of patients who received placebo plus standard care. ... Existing therapies are limited and associated with complications and a high failure

More from news
Approximately 3 fully matching, plus 2 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

A few days later Takeda announced it was paying $628m (82% share price premium) to buy Belgian company TiGenix NV and its lead asset Cx601 (darvadstrocel), an allogeneic stem cell therapy ... Option exercise (2 options). 640. TiGenix/Takeda. Cx601, lead
Deal Watch July 2016

Other deals where the licensee has committed real upfront money include Takeda's $28m upfront payment for ex-US rights to TiGenix's Cx601, a suspension of allogeneic adipose-derived stem ... Acquisition. 416. TiGenix/ Takeda. Cx601 - Stem cell treatment

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

TiGenix appoints Dr Marie Paule Richard

In her new role Richard will be responsible for the development of several products in Europe and the US, including rheumatoid arthritis and severe sepsis candidate Cx611 and Cx601, which is

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Healthcare PR Senior Account Manager: Salary TBC

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Scientific Director – Medical Communications - New York or Remot...: $100000 - $150000

Deputy Managing Director – Healthcare PR – Global Agency: Negotiable

Account Manager, Healthcare Advertising: £30 - 38, 000 (or -)

Senior Medical Writer, Principal Medical Writer, Scientific Dire...: £40000 - £75000 Bonus Benefits

Account Manager: Negotiable

Senior Medical Writer, MedComms Agency: £40 - 55, 000 according to skills and experience benefits

Senior Strategist/ Planner, Healthcare Marketing, London: Excellent package

Senior Writer, Healthcare Advertising, London: Excellent package

Digital Account Director – Health/ Pharma – Global Agency: Salary TBC

Market Access Consultant - Greater Manchester: Negotiable

Associate Scientific Director: Salary TBC

Account Director - Award Winning Healthcare Advertising Agency -...: £50000 - £68000

Principal Medical Writer / Editorial Director – Medical Communic...: £60, 000 - £80, 000

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Director or Senior Account Director: Salary TBC

Senior/ Market Access Consultant, UK, HOME BASED, £50-60K: Excellent package

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Sudler London - Senior Medical Writer: Competitive

Head of Market Access - International - Based Cambridge: Excellent Basic, Bonus and Flex Benefits

Senior Medical Writer: Salary is DOE

Graduate Scientific Editor: DOE

Leadership opportunity, Pricing & Market Access, UK, Substan...: Substantial six figure package

Account Director, Healthcare Advertising Agency: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Synergy Vision

Synergy Vision believe in delivering medical communications that make a difference to healthcare professionals and patients. Our synergy of pharma...

Latest intelligence

PM Society Digital Awards – the power of together: Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduce anyone in four simple steps: You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government: GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....